- Home
- MLYS vs DXYZ Comparison
MLYS vs DXYZ Comparison
Compare MLYS & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- DXYZ
- Stock Information
- Founded
- MLYS 2019
- DXYZ N/A
- Country
- MLYS United States
- DXYZ
- Employees
- MLYS N/A
- DXYZ N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- DXYZ
- Sector
- MLYS Health Care
- DXYZ
- Exchange
- MLYS Nasdaq
- DXYZ Nasdaq
- Market Cap
- MLYS 634.6M
- DXYZ 640.4M
- IPO Year
- MLYS 2023
- DXYZ 2024
- Fundamental
- Price
- MLYS $9.87
- DXYZ $55.17
- Analyst Decision
- MLYS Strong Buy
- DXYZ
- Analyst Count
- MLYS 2
- DXYZ 0
- Target Price
- MLYS $30.00
- DXYZ N/A
- AVG Volume (30 Days)
- MLYS 217.3K
- DXYZ N/A
- Earning Date
- MLYS 11-11-2024
- DXYZ N/A
- Dividend Yield
- MLYS N/A
- DXYZ N/A
- EPS Growth
- MLYS N/A
- DXYZ N/A
- EPS
- MLYS N/A
- DXYZ N/A
- Revenue
- MLYS N/A
- DXYZ N/A
- Revenue This Year
- MLYS N/A
- DXYZ N/A
- Revenue Next Year
- MLYS N/A
- DXYZ N/A
- P/E Ratio
- MLYS N/A
- DXYZ N/A
- Revenue Growth
- MLYS N/A
- DXYZ N/A
- 52 Week Low
- MLYS $7.95
- DXYZ N/A
- 52 Week High
- MLYS $16.91
- DXYZ N/A
- Technical
- Relative Strength Index (RSI)
- MLYS 31.09
- DXYZ N/A
- Support Level
- MLYS $12.00
- DXYZ N/A
- Resistance Level
- MLYS $13.37
- DXYZ N/A
- Average True Range (ATR)
- MLYS 0.92
- DXYZ 0.00
- MACD
- MLYS -0.17
- DXYZ 0.00
- Stochastic Oscillator
- MLYS 12.96
- DXYZ 0.00
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.